Research programme: therapeutic antiviral vaccines - Abivax/CIGB

Drug Profile

Research programme: therapeutic antiviral vaccines - Abivax/CIGB

Alternative Names: ABX-318; anti-HPV vaccine - Abivax/CIGB

Latest Information Update: 21 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BC Cancer Agency; Wittycell
  • Developer Abivax; Cuban Center for Genetic Engineering and Biotechnology; Wittycell
  • Class Papillomavirus vaccines
  • Mechanism of Action Immunostimulants; Natural killer cell receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cervical cancer; Cervical dysplasia; Human papillomavirus infections

Most Recent Events

  • 13 Feb 2014 Preclinical trials in Cervical cancer (prevention) in France
  • 13 Feb 2014 Preclinical trials in Cervical dysplasia in France
  • 13 Feb 2014 Preclinical trials in Human papillomavirus infections in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top